Clinical and experimental aspects of liposomal hydrocortisone treatment of bronchial asthma

Aim. Clinical and experimental validation of liposomal therapy with hydrocortisone as a perspective treatment of bronchial asthma (BA). Material and methods. Multistage trials of the liposomal treatment were made on 96 animals and in 137 BA patients. The decision on this treatment was based on the activity of bronchial inflammation and absence of contraindications. Liposomes were introduced endobronchially after a session of jet, high-frequency artificial lung ventilation. Results. Clinical endoscopic remission was achieved shortly after the treatment start in most of the patients. External respiration function and gas composition of blood improved, concentration of malonic dialdehyde lowered while catalase and glucose-6-phosphate dehydrogenase activity enhanced, inhalation sympathomimetics requirement reduced. Conclusion. Clinicomorphological and laboratory evidence obtained indicate high efficiency of liposomal therapy as an alternative to basic treatment of BA.